AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37601010
Drug: Romiplostim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (1 to 10 μg/kg for 9 weeks)
Trial: 37601885
Drug: Quadruplet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruplet therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone) followed by autologous hematopoietic cell transplantation (AHCT)
Trial: 37602376
Drug: FFR-guided PCI
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-guided PCI using zotarolimus drug-eluting stents
Trial: 37602458
Drug: Genotyping group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotyping group (high-risk subgroup received candesartan 8 mg/day for 6 weeks; low-risk subgroup received perindopril 4 mg/day)
Trial: 37602458
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not genotyped, received perindopril 4 mg/day)
Trial: 37603328
Drug: Teriflunomide, 14
RxNorm normalized name: Teriflunomide, 14 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide, 14 mg daily
Trial: 37603835
Drug: Treat-to-target strategy
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target strategy with pan-enteric capsule endoscopy (PCE)
Trial: 37604637
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prophylactic antibiotics administered within 24 hours
Trial: 37604637
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of prophylactic antibiotics administered within 24 hours
Trial: 37604637
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prophylactic antibiotics
Trial: 37604637
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of prophylactic antibiotics
Trial: 37604662
Drug: Metoclopramide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide + 4 mg dexamethasone
Trial: 37604662
Drug: Metoclopramide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide + 16 mg dexamethasone
Trial: 37604662
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (4 mg)
Trial: 37604662
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (16 mg)
Trial: 37604981
Drug: Glasdegib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib plus intensive chemotherapy (cytarabine and daunorubicin)
Trial: 37604981
Drug: Glasdegib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib plus non-intensive chemotherapy (azacitidine)
Trial: 37604988
Drug: FUS-MB treatment
RxNorm normalized name: Ionosol-MB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUS-MB treatment delivered before 1st and 5th fractions of RT (within 1 hour)
Trial: 37606364
Drug: Oral lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipid nanocrystal (LNC) amphotericin B + flucytosine (1.8 g/d for 2 weeks, then 1.2 g/d for 6 weeks)
Trial: 37606364
Drug: Oral lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipid nanocrystal (LNC) amphotericin B with IV loading doses + flucytosine
Trial: 37606606
Drug: CBD daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD daily in cycle 1
Trial: 37606641
Drug: Regorafenib (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (starting dose 72 mg/m2/day) with vincristine (1.5 mg/m2 on days 1 and 8) and irinotecan (50 mg/m2 on days 1-5)
Trial: 37606641
Drug: Regorafenib (MTD/RP2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (MTD/RP2D of 82 mg/m2 in sequential schedule)
Trial: 37606672
Drug: EC-IC bypass
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-IC bypass surgery plus medical therapy (surgical group; n=161)
Trial: 37606672
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (medical group; n=163)
Trial: 37606856
Drug: Neurotropic infections
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropic infections (viral, bacterial, protozoal) assessed through serology testing in patients treated with immune checkpoint inhibitors (ICI).
Trial: 37607096
Drug: Chimeric Antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Antigen Receptor T Cell Manufacturing using CliniMACS Prodigy
Trial: 37607203
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) for 30 minutes each morning for 3-4 weeks
Trial: 37607457
Drug: Non-HCT treatment
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-HCT treatment
Trial: 37607644
Drug: Propylene glycol-free
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylene glycol-free melphalan (PGF-Mel) at 140 to 200 mg/m²
Trial: 37607780
Drug: Anifrolumab intensified
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab intensified regimen (IR) 900 mg for the first 3 doses followed by 300 mg every 4 weeks
Trial: 37607780
Drug: Anifrolumab basic
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab basic regimen (BR) 300 mg every 4 weeks
Trial: 37607809
Drug: Tapering TNFi
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering TNFi to discontinuation
Trial: 37608269
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml group (ESB with 10 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 7 ml of saline 0.9%)
Trial: 37608269
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml group (ESB with 15 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 12 ml of saline 0.9%)
Trial: 37608287
Drug: Invimestrocel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invimestrocel plus standard treatment
Trial: 37608315
Drug: Amantadine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine administered intravenously for five days at a dosage of 100 mg bid.
Trial: 37608315
Drug: Amantadine (if
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (if non-responders, dosage doubled from day three to five).
Trial: 37608315
Drug: Amantadine treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine treatment.
Trial: 37608909
Drug: Pressure biofeedback-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure biofeedback-guided DCFM strength training and conventional treatment
Trial: 37608909
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and conventional treatment
Trial: 37609003
Drug: Dodecafluoropentane emulsion
RxNorm normalized name: dodecafluoropentane emulsion (DDFPe)
DrugBank: Perflenapent (DB11625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dodecafluoropentane emulsion (DDFPe) administered via intravenous infusion at doses of 0.05, 0.10, or 0.17 mL/kg while breathing supplemental oxygen prior to each 2 Gy fraction of radiotherapy (30 fractions over 6 weeks) along with standard-of-care chemotherapy (temozolomide).
Trial: 37609003
Drug: Dodecafluoropentane emulsion
RxNorm normalized name: dodecafluoropentane emulsion (DDFPe)
DrugBank: Perflenapent (DB11625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dodecafluoropentane emulsion (DDFPe) administered at 0.1 mL/kg dose level.
Trial: 37609318
Drug: Brief Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Cognitive Behavioral Therapy
Trial: 37609358
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of high-dose vs low-dose treprostinil
Trial: 37609651
Drug: First-line anti-seizure
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-seizure medications (ASMs) as substitution therapy
Trial: 37609651
Drug: Second-line anti-seizure
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line anti-seizure medications (ASMs)
Trial: 37609698
Drug: Cangrelor at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor at the start of PCI plus prasugrel at the end of infusion
Trial: 37609714
Drug: Neoadjuvant pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant pertuzumab and trastuzumab fixed-dose combination administered subcutaneously plus taxane-based chemotherapy
Trial: 37609778
Drug: Breast-conserving surgery
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving surgery and endocrine therapy (no other systemic therapy)
Trial: 37610332
Drug: Nurse-led package
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led package of care (non-pharmacological treatment)
Trial: 37611121
Drug: Divarasib (GDC-6036)
RxNorm normalized name: calcium carbonate
DrugBank: Divarasib (DB17488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divarasib (GDC-6036) administered orally once daily at doses ranging from 50 to 400 mg
Trial: 37611156
Drug: Busulfan 80
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 80 mg/m2 as outpatients on days -20 and -13 before transplant, Fludarabine 40 mg/m2 on days -6 to -3, busulfan dosed to achieve a target AUC of 20,000 mol/min for the whole course.
Trial: 37611174
Drug: ASICA app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ASICA app for monthly total-skin self-examinations (TSSE)
Trial: 37611246
Drug: Berberine 500
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine 500 mg TID for 20 weeks
Trial: 37612102
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation for patients with severe vitamin C depletion
Trial: 37612114
Drug: Dual hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual hormone fully closed loop (DHFCL)
Trial: 37612114
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (HCL or treatment with multiple daily insulin injections + FGM/CGM)
Trial: 37612115
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg CBN
Trial: 37612115
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CBN
Trial: 37612300
Drug: mRNA-1273.214 (50-µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273.214 (50-µg)
Trial: 37612300
Drug: mRNA-1273 (50-µg)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50-µg)
Trial: 37612310
Drug: SARS-CoV-2 immunity
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 immunity after two vaccine doses
Trial: 37612608
Drug: IPF patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPF patients with antifibrotic therapy at enrolment
Trial: 37612610
Drug: Biopsy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsy combined with same-session MR-guided LITT therapy followed by CRT
Trial: 37612621
Drug: Biweekly single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly single-dose actinomycin D (1.25 mg/m² IV pulse)
Trial: 37612621
Drug: Multiday methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiday methotrexate therapy
Trial: 37612698
Drug: Take home
RxNorm normalized name: Sodium Fluoride 5 mg in 1 g DENTAL GEL, DENTIFRICE [Take Home Fluoride Cool Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take home naloxone (THN) from participating harm reduction and drug treatment sites
Trial: 37614541
Drug: Tafolecimab 450
RxNorm normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafolecimab 450 mg every 4 weeks (Q4W)
Trial: 37614821
Drug: Intracerebroventricular CLN5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracerebroventricular CLN5 gene therapy
Trial: 37614943
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy after 3 months of DAPT
Trial: 37615485
Drug: Carboplatin-based chemotherapy
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin-based chemotherapy alone
Trial: 37615836
Drug: Nemolizumab (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab (drug treatment)
Trial: 37615989
Drug: TLC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC with MTM (intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact, plus pharmacist-referral for prescription medications)
Trial: 37615989
Drug: TLC (intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC (intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact)
Trial: 37616221
Drug: Trivalent Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent Influenza HA vaccine (TIV)
Trial: 37616289
Drug: A7+TouchCare insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A7+TouchCare insulin patch pump system
Trial: 37616289
Drug: Omnipod insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omnipod insulin pump system
Trial: 37616301
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) 8 mg plus DEC and ALB
Trial: 37616301
Drug: Ivermectin (IVM)
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin (IVM) 0.2 mg/kg plus DEC 6 mg/kg and ALB 400 mg
Trial: 37616583
Drug: Fully closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully closed-loop with ultrarapid insulin lispro (CamAPS HX system)
Trial: 37616583
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy with continuous glucose monitoring (CGM)
Trial: 37619579
Drug: Adjuvant oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oral mitotane (two or three times daily, target plasma concentration of 14-20 mg/L) for 2 years
Trial: 37619579
Drug: Adjuvant oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oral mitotane
Trial: 37619584
Drug: IBIO123 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBIO123 (1 mg, 5 mg, or 10 mg)
Trial: 37619584
Drug: IBIO123 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBIO123 (10 mg)
Trial: 37619705
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and hydrocodone
Trial: 37619980
Drug: SGN-B6A (antibody-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-B6A (antibody-drug conjugate directed to integrin beta-6)
Trial: 37620260
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of argipressin
Trial: 37620270
Drug: Automated clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated clinical decision support tool for intraoperative insulin dosing
Trial: 37620270
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin administration (control)
Trial: 37620294
Drug: High-carbohydrate fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate fluid diet (CFD) - 400 mL of maltodextrin orally 2 h before ERCP
Trial: 37620508
Drug: EGCG solution
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG solution (epigallocatechin-3-gallate)
Trial: 37620855
Drug: Drug Resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Resistance Mutation (DRM) testing
Trial: 37620929
Drug: SMART intervention
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART intervention (twice weekly football, martial arts, and dance coaching)
Trial: 37621674
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg daily for 7 days, followed by 5 mg/kg daily for 7 days)
Trial: 37621674
Drug: Azithromycin among
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin among participants receiving other antibiotics
Trial: 37621674
Drug: Azithromycin among
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin among antibiotic-naïve participants
Trial: 37621688
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine (L+C)
Trial: 37622035
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg on day 1, 100 mg twice daily thereafter for 15 days)
Trial: 37622681
Drug: Semaglutide (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (2.4 mg)
Trial: 37622738
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin 2.5 mg/kg every 3 weeks
Trial: 37622738
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin 3.4 mg/kg every 3 weeks
Trial: 37622738
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin (both doses)
Trial: 37623007
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 24 months of ADT, PBRT, and PLNRT
Trial: 37623203
Drug: Green coconut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green coconut water (330 mL)
Trial: 37623203
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (35 g of 70% dark chocolate)
Trial: 37623205
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral treatment intervention (IC)
Trial: 37623329
Drug: 0.05 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mmol/kg gadobutrol (half dose)
Trial: 37623329
Drug: 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg gadobutrol (single dose)
Trial: 37624619
Drug: Pirtobrutinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib monotherapy (200 mg once daily)
Trial: 37624900
Drug: Graded Exposure
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded Exposure Treatment (GET Living)
Trial: 37624901
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus intervention (pain coping skills training and optional support for opioid taper)
Trial: 37625235
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 3 weeks for 22 cycles with platinum-based chemotherapy and bevacizumab
Trial: 37625235
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with platinum-based chemotherapy and bevacizumab
Trial: 37625518
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg JNJ-10450232 (NTM-006)
Trial: 37625518
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg JNJ-10450232 (NTM-006)
Trial: 37625526
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of HOMA-IR (indicating higher insulin resistance)
Trial: 37625587
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose esomeprazole (80 mg bolus followed by 12 mg/h for 72 h and a second 80 mg bolus 12 h after the first one)